Lexeo Therapeutics, Inc. Common Stock (LXEO) Financial Ratios
5 years of historical data (2020–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
1.58
↓-36% vs avg
5yr avg: 2.47
30Y Low1.8·High3.1
ROE
↑
-85.4%
↓+99% vs avg
5yr avg: -11470.2%
30Y Low-85%·High-85%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
LXEO Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Lexeo Therapeutics, Inc. Common Stock currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Market Cap | $320M | $209M | $358M | — | — | — |
| Enterprise Value | $295M | $184M | $248M | — | — | — |
| P/E Ratio → | -1.88 | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — |
| P/B Ratio | 1.58 | 1.79 | 3.15 | — | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
LXEO EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
LXEO Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -85.4% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | 100.0% | 100.0% | 100.0% |
| Operating Margin | — | — | — | -9252.1% | -3055.9% | -884.9% |
| Net Profit Margin | — | — | — | -9063.8% | -3055.0% | -993.8% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| ROE | -85.4% | -85.4% | -22855.1% | — | — | — |
| ROA | -68.6% | -68.6% | -56.1% | -50.7% | -60.9% | -17.5% |
| ROIC | -166.2% | -166.2% | — | — | — | — |
| ROCE | -85.8% | -85.8% | -66.7% | -57.0% | -64.0% | -16.0% |
LXEO Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $35M exceeds total debt of $10M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Debt / Equity | 0.08 | 0.08 | 0.10 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.21 | -0.97 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | -927.77 | -927.77 | -334.21 | -664.93 | — | -31.18 |
Net cash position: cash ($35M) exceeds total debt ($10M)
LXEO Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Lexeo Therapeutics, Inc. Common Stock's current ratio of 5.52x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 5.58x to 5.52x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Current Ratio | 5.52 | 5.52 | 7.21 | 5.58 | 18.35 | 42.15 |
| Quick Ratio | 5.52 | 5.52 | 7.21 | 5.58 | 18.35 | 42.15 |
| Cash Ratio | 5.32 | 5.32 | 7.05 | 5.39 | 18.24 | 42.10 |
| Asset Turnover | — | — | — | 0.01 | 0.01 | 0.02 |
| Inventory Turnover | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — |
LXEO Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Lexeo Therapeutics, Inc. Common Stock returns 0.0% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $32M | $27M | $25M | $25M | $25M |
Peer Comparison
Compare LXEO with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 LXEOYou | $320M | -1.9 | — | — | — | — | -85.4% | -166.2% | — |
 RCKT | $398M | -1.8 | — | — | — | — | -60.3% | -63.2% | — |
 KRYS | $9B | 43.4 | 49.2 | 46.3 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
 SGMO | $22M | -0.2 | — | — | 100.0% | -179.9% | -185.4% | -178.8% | — |
 RARE | $3B | -4.5 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 FOLD | $5B | -164.8 | 114.9 | 152.4 | 87.3% | 5.4% | -11.6% | 5.3% | 11.5 |
 ACAD | $4B | 9.9 | 26.9 | 36.7 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
 ARWR | $11B | -6389.3 | 90.4 | 69.6 | 97.1% | 11.9% | -0.5% | 9.3% | 3.0 |
 NTLA | $2B | -3.6 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 CRSP | $5B | -8.1 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 5 years · Updated daily
See LXEO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LXEO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare LXEO vs RCKT
Side-by-side business, growth, and profitability comparison vs Rocket Pharmaceuticals, Inc..
Start ComparisonLXEO — Frequently Asked Questions
Quick answers to the most common questions about buying LXEO stock.
What is Lexeo Therapeutics, Inc. Common Stock's P/E ratio?
Lexeo Therapeutics, Inc. Common Stock's current P/E ratio is -1.9x. This places it at the 50th percentile of its historical range.
What is Lexeo Therapeutics, Inc. Common Stock's ROE?
Lexeo Therapeutics, Inc. Common Stock's return on equity (ROE) is -85.4%. The historical average is -85.4%.
Is LXEO stock overvalued?
Based on historical data, Lexeo Therapeutics, Inc. Common Stock is trading at a P/E of -1.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.